ADMET and DMPK

Scope & Guideline

Advancing drug discovery through innovative research.

Introduction

Welcome to the ADMET and DMPK information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of ADMET and DMPK, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1848-7718
PublisherIAPC PUBLISHING
Support Open AccessYes
CountryCroatia
TypeJournal
Convergefrom 2013 to 2024
AbbreviationADMET DMPK / ADMET DMPK
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressS ALICA 4, ZAGREB HR-10000, CROATIA

Aims and Scopes

The journal 'ADMET and DMPK' focuses on the intersection of drug absorption, distribution, metabolism, excretion, and toxicity (ADMET) alongside drug metabolism and pharmacokinetics (DMPK). It serves as a platform for researchers to publish studies that contribute to the understanding of how drugs behave in biological systems, their efficacy, and safety profiles.
  1. ADMET Profiling:
    Research focusing on the absorption, distribution, metabolism, excretion, and toxicity of drugs, providing insights into their pharmacological behavior and safety.
  2. Drug Formulation and Delivery Systems:
    Studies on the development and optimization of drug delivery systems, including nanomaterials and liposomes, aimed at enhancing drug efficacy and bioavailability.
  3. Electrochemical Sensing and Biosensors:
    Innovative methodologies involving electrochemical sensors for detecting drug compounds and biomarkers, which are crucial for pharmacokinetic studies and therapeutic monitoring.
  4. Pharmacokinetics and Modeling:
    Research involving the modeling of drug pharmacokinetics, including novel approaches to predict drug behavior in vivo, which is essential for drug development.
  5. Nanotechnology in Drug Development:
    Exploration of nanotechnology applications in drug formulation, delivery, and diagnostics, highlighting the transformative potential of nanomaterials in enhancing therapeutic outcomes.
The journal 'ADMET and DMPK' has seen a rise in specific themes that reflect current trends in drug development and delivery. These emerging areas indicate the journal's adaptability to the evolving landscape of pharmaceutical research.
  1. Nanomaterials and Drug Delivery Innovations:
    There is an increasing focus on the application of nanomaterials for drug delivery, enhancing bioavailability, and overcoming biological barriers, which is crucial for developing effective therapies.
  2. Electrochemical Biosensors for Biomarker Detection:
    The trend towards using advanced electrochemical methods for detecting biomarkers and drugs highlights the importance of rapid and sensitive diagnostic tools in pharmacokinetics.
  3. Sustainable and Green Chemistry Approaches:
    Research emphasizing environmentally friendly synthesis methods for drug compounds and materials is gaining traction, reflecting a broader commitment to sustainability in pharmaceutical sciences.
  4. Advanced In Vitro Models for Drug Testing:
    The emergence of sophisticated in vitro models, including 3D cell cultures and organ-on-a-chip systems, underscores a shift towards more predictive and ethical approaches in drug testing.
  5. Personalized Medicine and Pharmacogenomics:
    An increasing interest in the interplay between genetics and drug response is evident, indicating a trend towards personalized medicine that tailors treatments based on individual genetic profiles.

Declining or Waning

While 'ADMET and DMPK' continues to advance in various areas, certain themes seem to be losing prominence in recent publications. This shift may reflect evolving research priorities or emerging technologies overshadowing older methodologies.
  1. Traditional Pharmaceutical Formulations:
    Research focusing on conventional drug formulation techniques is becoming less frequent as new technologies, particularly nanotechnology and advanced delivery systems, gain traction.
  2. Basic Pharmacological Studies:
    Studies that solely focus on basic pharmacological effects without integrating ADMET or DMPK perspectives are declining, as the journal emphasizes comprehensive approaches that include these critical factors.
  3. Animal Studies in Drug Development:
    There is a noticeable decrease in studies relying solely on animal models for drug testing, as the field moves towards more ethical and predictive in vitro models, including organ-on-a-chip technologies.

Similar Journals

XENOBIOTICA

Innovating Insights into Chemical Substances and Life.
Publisher: TAYLOR & FRANCIS LTDISSN: 0049-8254Frequency: 12 issues/year

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

Pharmaceutical Sciences

Pioneering research at the intersection of science and health.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

International Journal of Pharmacology

Advancing the Frontiers of Pharmacological Research
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

BMC Pharmacology & Toxicology

Advancing knowledge in pharmacology and toxicology.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

AAPS PHARMSCITECH

Delivering Cutting-edge Insights for Public Health Advancements
Publisher: SPRINGERISSN: 1530-9932Frequency: 1 issue/year

AAPS PHARMSCITECH is a prestigious peer-reviewed journal published by Springer, focusing on the dynamic field of pharmaceutical sciences and technology. With an ISSN of 1530-9932, it provides a vital platform for disseminating cutting-edge research that spans key areas including drug discovery, pharmacology, toxicology, and ecological impacts of pharmaceuticals. The journal is recognized for its rigorous scientific contributions, currently holding a commendable Q2 quartile ranking across several relevant categories, including Agronomy and Crop Science, Aquatic Science, and Medicine in 2023. Notably, it ranks 43rd out of 183 in the Scopus Pharmacology, Toxicology, and Pharmaceutics category, placing it in the 76th percentile of its field. Aiming to foster innovation and collaboration among researchers, professionals, and students, AAPS PHARMSCITECH is committed to advancing scientific knowledge and addressing contemporary challenges in pharmaceutical sciences. The journal offers various access options to ensure wide dissemination of research findings, making it an essential resource for those dedicated to enhancing public health through pharmaceutical advancements.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pioneering research at the intersection of chemotherapy and oncology.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Journal of Reports in Pharmaceutical Sciences

Connecting Scholars and Practitioners in Drug Development.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Clinical Pharmacology in Drug Development

Bridging research and practice in drug development.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Innovating Solutions for Modern Pharmaceutical Challenges
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Exploring the Nexus of Science and Drug Development
Publisher: MARY ANN LIEBERT, INCISSN: 1540-658XFrequency: 8 issues/year

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.